Abstract Number: 0048 • ACR Convergence 2023
Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares
Background/Purpose: Gout is the most frequent form of inflammatory arthritis, with episodes of self-resolving acute inflammation in the joint caused by the deposition of monosodium…Abstract Number: 0246 • ACR Convergence 2023
Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies
Background/Purpose: In patients with refractory gout, the inability to maintain serum uric acid (sUA) levels < 6 mg/dL leads to severe clinical manifestations for which…Abstract Number: 0315 • ACR Convergence 2023
Identification of Calcium Crystals in End-Stage Osteoarthritis with Raman Spectroscopy
Background/Purpose: Calcium containing crystals in osteoarthritis (OA) are of interest as they potentially stimulate the NRLP-3 inflammasome and may become treatable with novel therapeutics. Previous…Abstract Number: 0812 • ACR Convergence 2023
Length of Synovial Fluid Monosodium Urate Crystals According to Sonographic Articular Deposits: Advancing in the Crystallization Process
Background/Purpose: We described bands of fibers having deposited orderly arrayed monosodium urate (MSU) crystals suggesting the need for protein templates to start crystallization [PMID 9709185].…Abstract Number: 0814 • ACR Convergence 2023
Treat-to-target Urate-lowering Therapy Reduces Gout Flare Burden: Post-hoc Analysis of a Multicenter, Randomized, Double-blind, Non-inferiority Trial
Background/Purpose: To optimally manage gout, the ACR recommends a treat-to-target (T2T) strategy, which entailsthe titration of urate-lowering therapy (ULT) to achieve and maintain a serum…Abstract Number: 0815 • ACR Convergence 2023
Intermittent Fasting Reduces Crystal-induced Inflammation
Background/Purpose: Inflammation induced by monosodium urate (MSU) and calcium pyrophosphate (CPP) crystals depends on interleukin (IL)-1β activated by the NLRP3 inflammasome. The inflammatory response can…Abstract Number: 1100 • ACR Convergence 2023
A Comparison of Characteristics of Patients with Crystalline and Septic Arthritis Confirmed by Synovial Fluid Analysis: Towards the Development of a Diagnostic Rule
Background/Purpose: Distinguishing crystalline from septic arthritis is a common challenge in patients admitted with acute joint inflammation. Arthrocentesis for synovial fluid analysis is considered the…Abstract Number: 1101 • ACR Convergence 2023
Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic Hyperuricemia
Background/Purpose: Whether the presence of subclinical monosodium urate (MSU) crystal deposition leads to a pro-inflammatory state in asymptomatic hyperuricemia (AH) is unknown. We aimed to…Abstract Number: 1115 • ACR Convergence 2023
EULAR Recommendations for the Use of Imaging in the Diagnosis and Management of Crystal-induced Arthropathies in Clinical Practice
Background/Purpose: The multifaceted clinical presentation in crystal-induced arthropathies (CiA) poses challenges to imaging. Our goal was to formulate evidence-based recommendations on the use of imaging…Abstract Number: 1118 • ACR Convergence 2023
The Nomenclature of Calcium Pyrophosphate Deposition (CPPD) Disease – Results of a Systematic Literature Review for the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) CPPD Nomenclature Project
Background/Purpose: Despite prior attempts at standardising terminology of calcium pyrophosphate deposition (CPPD) disease (including the 2011 EULAR recommendations for CPPD terminology and diagnosis), many different…Abstract Number: 1121 • ACR Convergence 2023
Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials
Background/Purpose: To this date, a causal relationship between febuxostat and cardiovascular disease remains controversial as comparison between trials can be challenging and may lead to…Abstract Number: 1900 • ACR Convergence 2022
CoLchicine for Treatment of OsteoArthritis of the Knee (CLOAK)-A Double-blind, Placebo-controlled Trial
Background/Purpose: Knee osteoarthritis (OA) is an inflammatory disease, with a probable role for IL-1b. Calcium and urate crystals may promote OA by activating the NLRP3…Abstract Number: 2208 • ACR Convergence 2022
Diagnostic Performance of Hip Ultrasound in Calcium Pyrophosphate Deposition Disease
Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a chronic and potentially incapacitating disease. The reference standard for its diagnosis is the identification of calcium pyrophosphate…Abstract Number: 1145 • ACR Convergence 2022
The Prostate Plays a Role in Serum Urate Levels and the Risk of Gout in Men
Background/Purpose: Men have higher serum urate (SU) and increased prevalence of gout compared to pre-menopausal women. Xanthine oxidoreductase (XOR), encoded by the XDH gene, is…Abstract Number: 1791 • ACR Convergence 2022
Point-of-Care Multi-Energy Photon-Counting CT for Earlier Non-Invasive Diagnosis of Gout and Calcium Pyrophosphate Deposition Disease
Background/Purpose: While the definitive diagnosis of gout and calcium pyrophosphate deposition disease (CPPD) is still based on the identification of characteristic crystals in synovial fluid…
- 1
- 2
- 3
- …
- 5
- Next Page »